AllSci News
US Federal Circuit reinstates Teva’s patent on anti-CGRP headache drug in case against Eli Lilly
Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc. (Israel) received a reversal from the US Court of Appeals for the Federal…
MeiraGTx Holdings raises USD 100m in underwritten public offering
MeiraGTx Holdings plc (Nasdaq: MGTX) announced a USD 100 million underwritten public offering of ordinary shares, with proceeds directed toward extending...
GlycoNex puts ADC targeting aberrant glycosylation into first-in-human for GI cancers
GlycoNex, Inc. (4168), a Taiwan-based clinical-stage biotechnology company, announced on April 14 that Japan's Pharmaceuticals and Medical Devices Agency...
Marengo's invikafusp alfa shows complete responses in metastatic breast cancer trial
Marengo Therapeutics reported initial Phase 2a results from the STARt-002 trial of invikafusp alfa combined with sacituzumab govitecan (TRODELVY) in heavily...
Acurx closes USD 7.1m share offering to support antibiotic development
Acurx Pharmaceuticals (NASDAQ: ACXP), a Staten Island, New York-based biopharmaceutical company developing small molecule antibiotics for difficult-to-treat...
Kailera sets IPO record with Nasdaq listing set to raise at least USD 625m
Kailera Therapeutics (Nasdaq: KLRA), a Waltham, Massachusetts-based clinical-stage biotechnology company focused on obesity treatment, priced its initial...
Mount Sinai Health System adopts Sophia Genetics SOPHiA DDM platform for cancer genomics sequencing
Mount Sinai Health System has adopted the SOPHiA DDM platform from Sophia Genetics (NASDAQ: SOPH), a cloud-native AI genomics company, to support...
Kestrel's pan-KRAS inhibitor swoops into Phase I for advanced solid tumors
Kestrel Therapeutics, a Watertown, Massachusetts-based biotechnology company, has opened a first-in-human Phase I clinical trial for KST-6051, an oral...
Trevi Therapeutics raises USD 150 million in underwritten public offering of common stock
Trevi Therapeutics (NASDAQ: TRVI), a New Haven, Connecticut-based clinical-stage biopharmaceutical company focused on chronic cough, has priced an...
University of Delaware receives USD 1.36m NIH grant for ephrin signaling research
The University of Delaware has received a USD 1.36 million R01 research grant from the National Institute of General Medical Sciences to investigate how a...
University of North Carolina receives USD 1.08m NHLBI R35 award for platelet biology research
The University of North Carolina at Chapel Hill has received an NHLBI R35 award through NIH research grants totaling USD 1,081,420 for the current budget...
University of Miami receives USD 3.15m NIH grant for neonatal genome sequencing antisense therapy
The University of Miami School of Medicine has received a USD 3.15 million NIH R01 grant from the National Human Genome Research Institute to build a...
Columbia University receives USD 3.2m NIH grant for RNA-binding protein mapping methods
Columbia University has received a USD 3.2 million R01 grant from the National Human Genome Research Institute to develop new computational and experimental...
METiS TechBio's enters MTS109 into Phase I for refractory autoimmune disease
Shanghai Changzheng Hospital has opened enrollment in the first-in-human MTS109 clinical trial (NCT07526350), testing an mRNA-encoded, lipid...
Shanghai Henlius's HLX3902 trispecific antibody enters Phase I trial for advanced solid tumours
Shanghai Henlius Biotech, the HKEX-listed Chinese biopharmaceutical company, has registered a first-in-human Phase I clinical trial for HLX3902, a...
The AllSci Brief
Systematic R&D and deal news. Daily.